Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease, after preliminary results proved disappointing. Shares in ...

When pharmaphorum last spoke with MRM Health founder and CEO Sam Possemiers at JP Morgan, he told us about his company’s microbiome-based therapy for ulcerative colitis. At LSX USA in Boston last ...

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...

The UK government has said it will accept all 44 recommendations made in a recently published report on using AI tools in the NHS, including continual monitoring after deployment. This morning, the ...

Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...